Access Pharmaceuticals, Inc.
Wikipedia on Answers.com:
Top
Access Pharmaceuticals, Inc.
 |
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (December 2008) |
| Type | Publicly traded |
|---|---|
| Industry | Biomedicine |
| Headquarters | Dallas, Texas, USA |
| Products | MuGard |
| Website | http://www.accesspharma.com |
Access Pharmaceuticals, Inc. is a biopharmaceutical company based in Dallas, Texas.[1] It uses nanotechnology to modify existing medications to improve their efficacy and tolerance.
As of June 2008, Access has one product approved by the Food and Drug Administration (FDA), namely MuGard for the management of oral mucositis.[1] In September 2010, Access received its first U.S. purchase order for MuGard and as of fall 2010 continued to receive more and more prescriptions for the product. Also, two products are in clinical trials, ProLindac, a drug that contains the DACH-platinum oxaliplatin (an anti-ovarian cancer agent)[2], and a product with phenylbutyrate, a HDAC inhibitor.
In 2009 the company reported on preclinical studies of its agent Angiolix, a monoclonal antibody that binds to lactadherin and inhibits angiogenesis.[3]
References
- ^ a b Company profile at the New York Times, date March 20, 2009
- ^ The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Transactions, 2010, 39, 8113-8127
- ^ Angiolix Results
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Access Pharmaceuticals, Inc..
Read more